P53.04 Local Therapies vs. Specific TKIs as the Initial Treatment for Oligo-Recurrent Lung Adenocarcinoma With Driver Mutations

Several studies have reported the efficacy of local therapies for lung cancer patients with postoperative oligo-recurrence. However, preference ablative over specific tyrosine-kinase inhibitors oligo-recurrence driver mutations remains controversial. We aimed to investigate optimal initial treatment strategy in mutations. Among 2,159 adenocarcinoma who underwent surgical resection at our institute between 2008 and 2017, we retrospectively evaluated 272 recurrence. Oligo-recurrence was defined as 1-3 recurrent lesions. investigated focusing on post-recurrence prognoses. The median follow-up period 52 months. In total, 155 (57%) had mutations, therapies, were administered 37 100 patients, respectively. Of them, 70 (45%) met criteria oligo-recurrence, 36 24 Compared inhibitors, significantly improved survival (p=0.043) but not progression-free (p=0.648) patients. also multivariable analyses adjusted number recurrence, results similar both (local therapies: hazard ratio, 0.45; 95% confidence interval, 0.20-1.02) 1.10; 0.61-1.96). Patients received even if they treatment, superior than those treated alone (p=0.027). Although a profound therapeutic benefit should be considered first choice oligo-recurrent cancer. Furthermore, combination may promising strategy.